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Abstract
The liver is an important site for thiamin metabolism, utilization, and storage. Little is known about the mechanism of thiamin uptake by
the human liver. In this study, we examined cellular and molecular aspects of the human liver thiamin uptake process using the human-
derived liver HepG2 cells as a model system. Our studies showed that the initial rate of thiamin uptake to be: (1) Na+-independent and occurs
with no detectable metabolic alterations in the transported substrate, (2) highly pH-dependent with diminished uptake upon decreasing
incubation buffer pH from 8.0 to 5.0, (3) higher following cell acidification compared to unacidified control cells, (4) saturable as a function
of concentration with an apparent Km of 7.7F 1.6 AM, (5) inhibited by the thiamin structural analogues oxythiamin and amprolium but not
by the unrelated organic cations tetraethylammonium (TEA) and N-methylnicotinamide (NMN), and (6) inhibited in a concentration-
dependent manner by the membrane transport inhibitor amiloride. Both of the recently cloned human thiamin transporters, i.e., SLC19A2 and
SLC19A3, were found to be expressed in liver HepG2 cells with the former being the predominant form. High promoter activity of the
predominant form, i.e., SLC19A2, was detected in HepG2 cells, and the minimal region of the SLC19A2 promoter required for its basal
activity in these cells was found to be encoded in a sequence between  356 and  36 and has multiple putative cis-regulatory elements.
Mutation of a number of these putative cis-elements diminished promoter activity of the SLC19A2 minimal region. These results show the
involvement of a specialized carrier-mediated mechanism for thiamin uptake by human liver HepG2 cells. In addition, SLC19A2 was found
to be the predominant thiamin uptake carrier expressed in these cells and its promoter displays a high level of activity in them.
D 2002 Elsevier Science B.V. All rights reserved.
Keywords: Thiamin uptake; Human liver; HepG2 cell; Transport mechanism; Gene expression; Gene promoter
1. Background
Thiamin (vitamin B1) is a member of the water-soluble
vitamin family of micronutrients. Thiamin is essential for
normal cellular functions, growth, and development. It
plays a critical role in normal carbohydrate metabolism
where it participates in the decarboxylation of pyruvic and
a-ketoglutamic acids, and in the utilization of pentose in
the hexose monophosphate shunt [1]. These reactions take
place predominately in the liver. Thiamin deficiency in
humans leads to a variety of clinical abnormalities includ-
ing neurological and cardiovascular disorders [1–3]. Thia-
min deficiency represents a significant nutritional problem
in both developed and developing countries. In developed
countries, thiamin deficiency has been reported in a high
percentage of alcoholic and diabetic patients [4–9], in
patients with renal and intestinal diseases [10–12], and
in the elderly despite an average daily intake of the
vitamin that exceeds the recommended requirement [13].
Thiamin deficiency also occurs in thiamin-responsive
megaloblastic anemia (TRMA), an autosomal recessive
disorder characterized by manifestations that include sen-
sorineural deafness, and diabetes mellitus [14,15]. A
genetic defect in the recently cloned thiamin transporter
SLC19A2 is believed to be the cause of TRMA [16–19].
Thus, studies that are aimed at increasing our understand-
ing of how to optimize thiamin body homeostasis are of
significant importance.
All human cells, including those of the liver, lack the
ability to synthesize thiamin. Thus, they must obtain the
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vitamin from exogenous sources via transport across the
cell membrane. The liver is a major site of thiamin
metabolism, utilization, and storage [20,21]; thus it plays
an important role in regulating normal thiamin body
homeostasis. Previous physiological and biochemical stud-
ies with rat liver preparations have shown thiamin uptake
to be via a specialized, carrier-mediated mechanism [21–
25]. This system transports thiamin in exchange for intra-
cellular H+ in an electroneutral manner, i.e., thiamin+:H+
exchange [22]. Very little, however, is known about the
mechanism of thiamin uptake by the human liver. The aim
of this investigation was to study cellular and molecular
aspects of thiamin uptake by the human liver using human-
derived liver HepG2 cells as a model system. The results
show that thiamin uptake by human liver HepG2 cells
occurs via a specialized, carrier-mediated mechanism. The
study also shows that both of the recently cloned human
thiamin transporters, i.e., SLC19A2 and SLC19A3 [16–
19,26,27], are expressed in liver HepG2 cells with the level
of expression of SLC19A2 being considerably higher than
that of SLC19A3. In addition, the results show that the
recently cloned SLC19A2 promoter is highly active in
HepG2 cells and that the minimal region required for basal
promoter activity is encoded in a sequence between  356
and  36. Furthermore, this region appears to have a
number of putative cis-regulatory elements which, when
mutated, affect promoter activity.
2. Methods
3H-Thiamin (sp. act. 15–25 Ci/mmol; radiochemical
purity >97%) was obtained from American Radiolabeled
Chemicals Inc. (ARC), St. Louis, MO. Routine biochem-
icals and cell culture reagents were purchased from Sigma
Chemical Company (St. Louis, MO), and Life Technolo-
gies Incorporated (Rockville, MD). Fetal bovine serum
(FBS) was obtained from Omega Scientific (Tarzana,
CA). Liver HepG2 cells were obtained from American
Type Culture Collection (Rockville, MD). The radiochem-
ical purity of stock 3H-thiamin and the degree of metab-
olism of the transported thiamin into HepG2 cells were
checked by means of thin-layer chromatography using
cellulose gel pre-coated plates and a solvent system of
isopropanol/0.5 M acetate buffer, pH 4.5/water (65:15:20,
v/v) [28].
Liver HepG2 cells were grown and sub-cultured as
described by us previously [29,30]. Cells were used
between passages 29 and 39. Uptake studies were per-
formed on confluent monolayers (3–5 days post-conflu-
ence) incubated at 37 jC in Krebs–Ringer buffer (in mM:
133 NaCl, 4.93 KCl, 1.23 MgSO4, 0.85 CaCl2, 5 glucose,
5 glutamine, 10 HEPES and 10 MES, pH 7.4; unless
otherwise specified). In certain experiments, cells were
pretreated with the compound under study for a specific
period of time prior to the addition of 3H-thiamin and the
start of uptake experiments. Unless otherwise specified,
uptake was examined over a period of 3 min, i.e., initial
rate. Uptake reaction was terminated by the addition of
ice-cold buffer followed by rinsing and digestion of cells
with NaOH, neutralization with HCl, and counting the
radioactive level. Parallel wells were used to determine
protein concentrations using a Bio-Rad kit (Richmond,
VA).
In the study on the effect of cell acidification on thiamin
uptake by HepG2 cells, confluent monolayers of these cells
were incubated for 30 min in Krebs–Ringer buffer (K–R
buffer) in which NaCl was replaced with NH4Cl [28]. This
was followed by removal of the buffer, washing the
monolayers with KCl containing K–R buffer (KCl replaced
NaCl), and incubating the cells with 3H-thiamin in the same
KCl containing K–R buffer for 3 min. Results were
compared to 3H-thiamin uptake by cells pre-incubated for
30 min with a KCl containing K–R buffer (instead of
NH4Cl containing K–R buffer), with the rest of cells being
handled similarly.
2.1. Expression of SLC19A2 and SLC19A3 in liver HepG2
cells: semiquantitative RT-PCR
Semiquantitative PCR with specific primers for
SLC19A2 and SLC19A3 was performed on first-strand
cDNA generated from RNA (5 Ag) isolated from mature
confluent monolayers of HepG2 cells. The sequence of
the primers was as follows, for SLC19A2 they were: F
5V-GCTGCTGCAGTGTATATCATG-3V; R 5V-CACCAAA-
TACTAGGGCATAG-3V. For SLC19A3 they were: F 5V-
ACCTGACCAGTGCAGAG-3V; R 5V-GGTAATGAT-
GAAACTGATACATAC-3V. The RT reaction was primed
with either an oligo-dT primer, a random hexamer, or a
gene-specific primer. Each of these RT reactions were used
in separate PCRs with gene-specific primers and identical
results were obtained. A SuperScriptk First-Strand Syn-
thesis for RT-PCR kit (Life Technologies) was used as
described by the manufacturer. PCR conditions were: dena-
turation at 95 jC for 5 min; 30 cycles of 95 jC denatured for
30 s, 56 jC annealing for 30 s, 72 jC extension for 1 min,
and a final 7 min extension at 72 jC. The PCR product was
separated through a 2% agarose gel with images captured
using an Eagle Eyek II system (Stratagene, La Jolla, CA).
The amplified RT-PCR products were normalized to the
amplified h-actin RT-PCR product using the densitometry
program on the Eagle Eyek II System.
2.2. Promoter analysis: cell transfection and firefly luci-
ferase assay
Four micrograms of SLC19A2 promoter deletion con-
structs generated in our laboratory in a previous study
([31]; see Table 1) were transfected separately into human
liver HepG2 cells using Lipofectamine reagent (Life Tech-
nologies, Gaithersburg, MD) as described by us previously
H.M. Said et al. / Biochimica et Biophysica Acta 1567 (2002) 106–112 107
[31,32]. To normalize for transfection efficiency, the cells
were co-transfected with 100 ng of pRL-TK (Promega)
plasmid along with the promoter constructs. Total cell
lysate was prepared from cells 24 h post-transfection and
firefly luciferase activity was assayed using the Dual
luciferase kit (Promega) and a Turner Design 20/20 Lumin-
ometer (Sunnyvale, CA). The activity was normalized to
the Renilla luciferase activity from pRL-TK in the same
extract.
2.3. Mutational analysis
Mutations were introduced into the SLC19A2 minimal
promoter-luciferase constructs using a Stratagene site-direc-
ted mutagenesis kit and the manufacturers protocols. The
sequences were verified by the Laragen Sequencing Facility
(Los Angeles, CA). The mutated constructs were then tran-
siently transfected into HepG2 cells using the identical
method described earlier.
2.4. Statistical analysis
All transport data described in this paper are the result
of multiple separate uptake determinations and are
expressed as meanF S.E. in mol/mg protein/unit time.
Kinetic parameters of the saturable component of thiamin
uptake (i.e., Vmax and apparent Km) were determined
using a computerized model of the Michaelis–Menten
equation as described by Wilkinson [33]. Data on pro-
moter activity are expressed as meanF S.E. of at least
three independent experiments and are given as fold
expression over pGL3-Basic expression set arbitrarily at
one. Data were analyzed by regression analysis and the
Student’s t-test.
3. Results
3.1. General characteristics of thiamin uptake by human
liver HepG2 cells
Uptake of thiamin (15 nM) by HepG2 cells as a function
of time was linear for 3 min of incubation and occurred at a
rate of 9.2 fmol/mg protein/min (data not shown). Uptake
during this period occurred without metabolic alterations as
97% of the transported radioactivity was found, by thin-
layer chromatography (see Methods), to be in the form of
intact thiamin.
The role of Na+ in the incubation medium in thiamin
uptake by HepG2 cells was also examined by testing the
effect of its isosmotic replacement with another monovalent
cation (Li+) or with mannitol on the vitamin uptake. The
results showed that such replacement had no significant
effect on the initial rate of thiamin (15 nM) uptake
(61.4F 1.9, 69.5F 0.8, and 69.6F 1.8 fmol/mg protein/3
min in the presence of Na+ (control), Li+, and mannitol,
respectively). The effect of pretreating HepG2 (for 30 min)
cells with 0.5 or 1 mM of the Na–K–ATPase inhibitor
ouabain on uptake of 15 nM thiamin was also examined.
The result showed no effect of such treatment on thiamin
uptake (76.5F 3.6, 74.7F 0.5 and 77.5F 0.5 fmol/mg pro-
tein/3 min, in the absence and presence of 0.5 and 1 mM
ouabain, respectively).
In another study, we investigated the effect of changing
incubation buffer pH and intracellular pH on thiamin uptake
by HepG2 cells. Decreasing incubation buffer pH from 8.0 to
5.0 was found to be associated with a progressive decrease in
the initial rate of thiamin (15 nM) uptake (Fig. 1). Lowering
the intracellular pH of HepG2 cells (achieved as described in
Methods) led to a significant (P < 0.01) increase in thiamin
(15 nM) uptake compared to control (80.7F 1.3 and
281.8F 3.4 fmol/mg protein/3 min for control and acidified
cells, respectively). We also examined the effect of the
membrane transport inhibitor amiloride on thiamin (15 nM)
uptake by HepG2 cells. The results showed amiloride to
cause significant (P < 0.01 for all) inhibition in thiamin
uptake (72.6F 1.1, 61.7F 0.7, and 53.0F 0.9 fmol/mg pro-
tein/3 min for control and in the presence of 0.1 and 0.5 mM
amiloride, respectively).
We also examined the effect of incubation temperature on
the initial rate of thiamin (15 nM) uptake. The results showed
a significant (P < 0.01) decrease in the vitamin uptake upon
lowering the incubation temperature from 37 to 4 jC (72.8F
4.9 and 14.6F 0.8 fmol/mg protein/3 min, respectively).
3.2. Evidence for involvement of a specialized, carrier-
mediated mechanism for thiamin uptake by HepG2 cells
Two sets of studies were performed to address this issue.
In the first study, we examined the initial rate of thiamin
Fig. 1. Effect of incubation buffer pH on thiamin uptake by liver HepG2
cells. Monolayers were incubated in Krebs–Ringer buffer of varying pH at
37 jC. 3H-Thiamin (1 AM) was added to the incubation medium at the
onset of incubation. Initial rate of uptake (3 min) was then determined. Data
are meanF S.E. of four to six separate uptake determinations.
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uptake (3 min) as a function of substrate concentration in
the bathing medium (0.015–20 AM). The results showed
thiamin uptake to include a saturable component (Fig. 2).
Uptake by this component was determined by subtracting
uptake by simple diffusion from total thiamin uptake by
HepG2 cells at each substrate concentration. Uptake by
simple diffusion was calculated from the slope of the line
between uptake at high substrate concentration (1 mM) and
the point of origin. The apparent Km and Vmax of the
saturable component were then determined as described
in Methods and found to be 7.7F 1.6 AM and 5.8F 0.6
pmol/mg protein/3 min, respectively.
In the second study, we tested the effect of a 25 AM
concentration of the thiamin structural analogs oxythiamin
and amprolium, and a 100 AM concentration of the unre-
lated organic cations tetraethylammonium (TEA), and N-
methylnicotinamide (NMN) on the initial rate of 3H-thiamin
(15 nM) uptake by confluent HepG2 cells. The results
showed that while thiamin structural analogs oxythiamin
and amprolium cause a significant (P < 0.01) inhibition in
3H-thiamin uptake (64.6F 2.1, 49.3F 1.0, and 42.6F 0.8
fmol/mg protein/3 min for control and in the presence of
oxythiamin and amprolium, respectively), no inhibition in
thiamin uptake was observed in the presence of the unre-
lated organic cations (64.6F 2.1, 69.2F 1.5, and 69.4F 2.3
fmol/mg protein/3 min, for control and in the presence of
TEA and NMN, respectively).
3.3. Expression of SLC19A2 and SLC19A3 in HepG2 cells
In this study, we determined the relative expression of the
recently cloned human thiamin transporters SLC19A2 and
SLC19A3 in HepG2 cells. We used semiquantitative PCR
with specific primers for SLC19A2 and SLC19A3 as
described in Methods. The results showed that although
both of the human thiamin transporters are expressed in
HepG2 cells, the level of expression of SLC19A2 is approx-
imately 2.5-fold higher than that of SLC19A3 (Fig. 3).
3.4. Analysis of SLC19A2 promoter in HepG2 cells
SLC19A2 appears to be the predominant thiamin trans-
porter in HepG2 cells. Therefore, we examined the activity
of its promoter in these liver cells. We used the recently
cloned 5V regulatory region of the SLC19A2 gene (2210 bp)
fused to the firefly luciferase reporter gene [31]. The results
showed that the activity of the of SLC19A2 promoter in
DNA transfected HepG2 cells to be approximately 300-fold
higher compared to cells transfected with vector alone (Fig.
4). We then extended the study to determine the minimal
region of the SLC19A2 promoter that is required for its basal
activity in HepG2 cells. This was performed using deletion
constructs of the SLC19A2 promoter fused to the firefly
luciferase reporter gene (Table 1) that were previously
Table 1
Relative position and size of the SLC19A2 promoter and promoter deletion
constructs
Construct name Position Size
PGL3-P  2250 to  36 2214
PGL3-PD1  2179 to  36 2143
PGL3-PD2  1645 to  36 1609
PGL3-PD3  450 to  36 414
PGL3-PD4  429 to  36 393
PGL3-PD5  356 to  36 320
PGL3-PD6  317 to  36 281
PGL3-PD7  275 to  36 239
PGL3-PD8  139 to  36 103
PGL3-PD9  108 to  36 72
A of the translation initiation codon is considered as 1.
Fig. 3. Expression of SLC19A2 and SLC19A3 in liver HepG2 cells. Reverse
transcription reaction was performed using 5 Ag of total RNA isolated from
HepG2 cells using oligo-dT primer and an Invitrogen Superscript kit.
Subsequent PCRs were performed with equal amounts of first-strand cDNA
product using gene-specific primers in separate reactions since the products
were all similar in size. The final PCR product was run on a 2% agarose gel
with a GibcoBRL 1 kb marker.
Fig. 2. Initial rate of thiamin uptake by liver HepG2 cells as a function of
concentration. Monolayers were incubated for 3 min (initial rate) in Krebs–
Ringer buffer pH 7.4 at 37 jC in the presence of different concentrations of
thiamin. Uptake by the saturable component was determined as described in
Results. Data are meanF S.E. of four to seven separate uptake
determinations.
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generated in our laboratory [31]. The results showed the
minimal region to be encoded by a sequence between  356
and  36 (using the A of the ATG initiator methionine as
position + 1) (Fig. 4). Using computer analysis (MAT
Inspector and Ali Baba), we identified several putative
cis-regulatory elements in this minimal promoter region
which may be involved in the regulation of SLC19A2
expression in human liver HepG2 cells. This includes
putative binding sites for gut-enriched Krupple-like factor
(GKLF), nuclear factor 1 (NF1), activator protein 1 (AP1)
and stimulating factor 1 (SP1). To determine if any of these
putative cis-elements is important for activity of the minimal
promoter, we mutated these sites individually, then meas-
ured promoter activity of the mutated constructs as
described earlier. We also examined the effect of introducing
a non-specific mutation outside these putative cis-elements
for comparison. The results showed that mutating the AP1
site at  311, the SP1 site at  347, or introducing the non-
specific mutation at  278 has no effect on core promoter
activity. However, mutating the NF1 site at  291 or the
GKLF/SP1 at  234 led to a significant decrease (P < 0.01
for all) in promoter activity (Fig. 5). The GKLF site and SP1
site at  234 overlap and the mutation could effect either
site.
4. Discussion
The liver is a major site of thiamin metabolism, utiliza-
tion, and storage. Little, however, is known about the
mechanism of thiamin uptake by human liver cells. The
present study was aimed at addressing this issue using the
human-derived liver HepG2 cells as a model system. These
cells were chosen because they have proven to be a good
model in similar physiological investigations and have been
used to characterize transport of other nutrients and sub-
strates [29,30,34]. Uptake of thiamin by HepG2 cells was
Na+-independent as replacing Na+ in the incubation medium
with Li+ or mannitol did not affect thiamin uptake and that
ouabain (the inhibitor of Na+–K+–ATPase) failed to affect
the uptake process. Uptake, however, was found to be
highly pH dependent. Decreasing the incubation buffer pH
from 8.0 to 5.0 was associated with a progressive decrease
in thiamin uptake. On the other hand, cell acidification was
associated with a marked increase in thiamin uptake. These
findings are in line with the concept that thiamin is being
transported via a thiamin+:H+ exchange mechanism as
Fig. 5. Effect of mutating putative cis-elements in the SLC19A2 minimal
promoter region on promoter activity in HepG2 cells. Legend is as in Fig. 4.
Mutations were introduced as described in Methods.
Fig. 4. Activity of SLC19A2 promoter in HepG2 cells: identification of the minimal region required for basal activity. The size and position of different
promoter-luciferase constructs are shown on the left. The results of a luciferase assay for each construct following transient transfection into liver HepG2 cells
are shown on the right. Firefly luciferase activity was normalized relative to the activity of simultaneously expressed Renilla luciferase. The results are
expressed relative to the pGL3-basic vector which was set at 1, and represent the average of three independent experiments.
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suggested for the vitamin uptake by isolated basolateral
membrane vesicles of rat liver [22]. According to this
mechanism, increasing the magnitude of the outwardly
directed H+ gradient leads to an increase in thiamin uptake,
while decreasing the magnitude of the gradient leads to a
decrease in the vitamin uptake as observed in the present
study. It is interesting to also report here that amiloride, the
inhibitor of the Na+:H+ exchanger also inhibits thiamin
uptake by HepG2 cells. A similar effect for amiloride on
thiamin uptake has been observed in other cell types
including intestinal and renal epithelial cells [28,35–38].
These findings raise the possibility that long-term use of this
diuretic may lead to interference with normal thiamin body
homeostasis. Such a situation may exist, for example, in the
case of alcoholic patients with liver cirrhosis who are on
long-term use of diuretics to treat their fluid overload. Many
of these alcoholic patients are also thiamin-deficient but it is
unclear if the use of diuretics contributes to this abnormality.
Detailed investigation is required to address this issue.
The process of thiamin uptake by HepG2 cells appears to
be carrier-mediated as indicated by the saturation in the
substrate uptake as a function of concentration and the
inhibition in 3H-thiamin uptake by the thiamin structural
analogs oxythiamin and amprolium. The fact that none of
the unrelated organic cations affected the transport of the
cationic thiamin indicates that the uptake process is specific
in nature.
Our current investigation has also shed light on the
molecular nature of the transport system(s) involved in
thiamin uptake by the human liver HepG2 cells. Both of
the recently cloned human thiamin transporters SLC19A2
and SLC19A3 were found to be expressed in HepG2 cells.
However, the expression of SLC19A2 was more predom-
inant than that of SLC19A3, suggesting that the former
transporter may play a more prominent role in thiamin
uptake in liver cells. Focusing on the predominant SLC19A2
transporter, we examined the promoter activity of this gene
in liver HepG2 cells. This was performed by transfecting
HepG2 cells with the previously identified SLC19A2 pro-
moter fused to the firefly luciferase reporter gene [31] and
assaying for luciferase activity. Our results showed a very
high level of activity of SLC19A2 promoter in HepG2 cells.
This activity is significantly higher than that previously
observed in the human-derived intestinal epithelial Caco-2
cells (300- compared to 150-fold above activity of vector
transfected cells; Ref. [31]). It is interesting to also mention
here that the level of expression of endogenous RNA for
SLC19A2 in HepG2 and Caco-2 cells correlates well with
the activity of the transfected promoter (unpublished obser-
vations). These findings show that SLC19A2 is efficiently
expressed in HepG2 cells, and thus, may play an important
role in the normal liver thiamin uptake process. In analyzing
the activity of the SLC19A2 promoter in HepG2 cells, we
also sought to determine the minimal region of the promoter
that is required for its basal activity in this cell type. The
results showed the minimal region to be encoded in a
sequence between  356 and  36 (relative to the A of
the ATG initiation codon). This region was found to have a
CAAT box at position  305, is GC-rich, and has several
putative cis-elements including NF1, AP1, GKLF, and SP1
that may be involved in the regulation of transcription of the
SLC19A2 gene in liver cells. To test for a possible involve-
ment of these elements in the activity of the minimal
promoter in liver cells, we mutated these putative sites
individually and examined promoter activity of the mutated
constructs in HepG2 cells. We also examined the effect of
introducing a non-specific mutation outside these elements
on promoter activity of the minimal region. The findings
showed that while the non-specific mutation and the muta-
tions introduced at the AP1 or the SP1 site had no effect on
activity of the minimal promoter region, mutating the NF1
or GKLF/SP1 site led to a significant decrease in promoter
activity. These results suggest that the latter cis-elements
may play a role in the functionality of the SLC19A2
promoter in liver cells. Further studies are required to
confirm this suggestion. It is of interest to mention here
that a similar promoter region was found to be responsible
for basal activity of the SLC19A2 gene in intestinal epithe-
lial Caco-2 cells [31]. Mutational analysis of the minimal
SLC19A2 promoter in Caco-2 cells showed the GKLF/SP1
and NF1 sites were important for activity, however, the SP1
site was also determined to contribute to activity in these
intestinal cells (unpublished observations). This may sug-
gest that the observed differential activity of the SLC19A2
promoter in Caco-2 and HepG2 cells is partly due to the SP1
cis-regulatory element. Additional studies, however, are
needed to confirm this possibility.
In summary, results of this investigation demonstrate the
involvement of a specialized carrier-mediated mechanism
for thiamin uptake by human liver HepG2 cells. In addition,
SLC19A2 appears to be the predominant thiamin transporter
expressed in these cells and its promoter displays a high
degree of activity. Furthermore, the minimal region of the
SLC19A2 promoter required for its basal activity in HepG2
cells was found to be encoded by a sequence between  356
and  36 and contains a number of putative cis-elements
which may be involved in regulating its activity.
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